call us direct at 1-800-259-9622

Ingen Technologies Delivers Oxyview to QOSINA Corporation  

YUCAIPA, Calif., Sept. 9, 2008 (GLOBE NEWSWIRE)

Ingen Technologies, Inc. (Pink Sheets:ITEC), an emerging medical device manufacturer within the $4-Billion respiratory device market, announced today that it has fulfilled the first Oxyview(r) purchase order received from QOSINA Corporation earlier last week. QOSINA Corporation is now a strategic OEM partner with Ingen Technologies.

QOSINA Corporation, founded in 1980 and based in Edgewood-New York, is a leading global components supplier to the medical and pharmaceutical industries. Companies purchase from QOSINA to eliminate the cost of tooling their own components and to receive immediate delivery from inventory. This particular approach is useful to companies of all sizes, but has proven especially effective for small to mid-range manufacturing companies, as evidenced by QOSINA's broad customer base cultivated over the years. Recently QOSINA has developed an OEM relationship with Ingen Technologies, and has agreed to include Oxyview(r) with their existing product line of respiratory accessories.

The company has recently seen an increase with on-line Oxyview(r) purchases direct from patients as a result of national news exposure of the product. NewsUSA has recently featured Oxyview(r) in their national media coverage.

For more information please visit:

About Ingen Technologies, Inc.

Ingen is an emerging public company that introduced Oxyview(r) into the medical and aviation markets in early 2008, after receiving registration and classification from the US Food & Drug Administration. The company has expanded its distribution in North America and Asia, and continues to attract various OEM partners who manufacture products for the respiratory market. The company has a second product, OxyAlert(r), currently under evaluation by the US Food & Drug Administration.

Oxyview(r) provides a visual cue to the patient or administrator, indicating the continuous flow and volume of oxygen during therapy. It allows the user to be sure that they are receiving the proper oxygen level and alerts them if adjustments need to be made. This device will simplify the oxygen therapy process and save Medicare expenses associated with unnecessary service calls. According to Dr. Vlady Rozenbaum, Director of the National Emphysema/COPD Foundation, "This very small and simple to operate and yet very accurate gauging device provides a high measure of security to patients, who can quickly be alerted to malfunctioning equipment and take the necessary steps to correct the situation or immediately contact their oxygen provider. I have been using Oxyview(r) during my pulmonary rehabilitation sessions and I know of many patients who consider Oxyview(r) a very important part of their oxygen therapy."

According to the 2002 CDC Report, there are approximately 32 million people living in the United States that suffer from Chronic Obstructive Pulmonary Disease, more commonly known as "COPD," the major cause of hospitalizations and the fifth leading cause of death in the United States. A large portion of the COPD patients receive oxygen therapy and qualify in using the Oxyview(r). Ingen Technologies owns the patents and trademarks for Oxyview(r) and OxyAlert(r), and there are no other products that compete or simulate either of these two products within the medical industry

A Member of the Better Business Bureau
A Member of the Chamber of Commerce
A Licensed Business in the City of Yucaipa
A Registered & Licensed Manufacturer with FDA/DHS

The Ingen Technologies, Inc. logo is available at:

Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.

Contact Information

Ingen Technologies, Inc.
Chris Wirth, Director
(909) 790-7180
Fax: (909) 795-6340
[email protected]
35193 Avenue "A"
Yucaipa, California 92399

| Home | Products | Our Company | Contact Us | Our Technology |
| Customer Support | Oxyview® | Distributor Inquiry | Sitemap |
Designed By N-Ferno Design Studio - Copyright © 2008